MARKET WIREYahoo Finance Australia • 1d ago
Pharvaris N.V. (PHVS) stock price, news, quote and historyYahoo Finance Australia report covering Pharvaris N.V. (PHVS) market action, institutional positioning, and fundamental catalysts.
Why PHVS Stock Traded Steady Today — RQD Quant Desk Flash
$33.53 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $33.47
Pharvaris N.V. (PHVS) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C- • HOLD / WATCH
Cap $2.34B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on PHVS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is PHVS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Pharvaris N.V. (NASDAQ: PHVS) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $33.53 (0.00% 1D, market cap $2.34B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, PHVS ranks #167 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does PHVS compare to BHVN and PBH in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PHVS carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, BHVN (Biohaven Ltd.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $2.33B) and PBH (Prestige Consumer Healthcare Inc.) posts a C grade (62/100 RQD, P/E 12.1x, ROIC 13.8%, cap $2.32B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while PBH leads on capital efficiency (13.8% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for PHVS?
▼
For Pharvaris N.V. (PHVS), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #167 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $33.47 (-0.19%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 1.6% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY • 53.1% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C-
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE+0.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PHVS)Realized 20D OHLCV Swing Band: ±8.5%
Deterministic 5-Pillar Attribution (59/100 Composite)
🔍 WHY PHVS SCORES 59/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (22% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (22% of score)
FRED Regime × Technicals: 56% of 52W Range • RSI-14 at 59.4 (BULLISH MOMENTUM)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$30.02+2.9% Next Q
51
Q2 (-2Q)Grade C-$30.90+3.4% Next Q
54
Q3 (-1Q)Grade C$31.95+4.9% Next Q
56
CurrentGrade C-$33.53+0.2% Hist 90D α
59
Trajectory: C- (51) → C- (59)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the PHVS Bull Thesis Could Fail
Even with a 59/100 (C-) score, PHVS faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Company executives have done more routine share selling than personal cash buying lately.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($33.54) or 200D SMA ($31.08) invalidates the momentum regime and cuts Target Base ($33.68) toward Bear Floor ($26.27).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $PHVS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PHVS Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PHVS Stock Traded Steady Today — RQD Quant Desk Flash
Pharvaris N.V. (PHVS) slipped 0.00% to $33.53, trading at 56% of its 52-week range ($21.02 – $43.25). Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 56% of its 52-week range ($21.02 – $43.25) with RSI-14 at 59.4 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±8.5% around $33.53 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C- (Hold) backed by 52% gross margin and $65.4M annual free cash flow.
Live PHVS Headlines & Catalysts
MARKET WIRESeeking Alpha • 1d ago
Pharvaris N.V. (PHVS) Presents at 2026 HAEi Regional Conference Americas - SlideshowSeeking Alpha report covering Pharvaris N.V. (PHVS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com • 1d ago
Pharvaris stock reiterated Buy at H.C. Wainwright on HAE therapy potentialInvesting.com report covering Pharvaris N.V. (PHVS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga report covering Pharvaris N.V. (PHVS) market action, institutional positioning, and fundamental catalysts.
RISK WATCHBenzinga • 1d ago
Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks FadeBenzinga report covering Pharvaris N.V. (PHVS) market action, institutional positioning, and fundamental catalysts.
RISK WATCHhttps://www.siam.in/ • 1d ago
Pharvaris (PHVS) Slips 1.72% to $30.36, Holding the Midpoint of Its Recent Range - Bear Pennanthttps://www.siam.in/ report covering Pharvaris N.V. (PHVS) market action, institutional positioning, and fundamental catalysts.
CATALYSTBenzinga • 1d ago
This Allegion Analyst Turns Bullish; Here Are Top 5 Upgrades For FridayBenzinga report covering Pharvaris N.V. (PHVS) market action, institutional positioning, and fundamental catalysts.
CATALYSTBenzinga • 4d ago
This Monolithic Power Analyst Turns Bullish; Here Are Top 4 Upgrades For FridayAnalysts upgraded Incyte, Intel, Rivian and Monolithic Power, raising ratings and targets; MPWR’s target increased to $1,700.
MARKET WIREYahoo • 5d ago
Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific MeetingPivotal, Phase 3 CHAPTER-3 data selected for late-breaking oral presentation on Saturday, November 14ZUG, Switzerland, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company de
CATALYSTBenzinga • 5d ago
This Hilton Hotels Analyst Turns Bullish; Here Are Top 5 Upgrades For ThursdayAnalysts upgraded VF Corp, Hilton, Ares Capital, eBay and Wintrust Financial, raising targets for VF, Hilton, eBay and Wintrust.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (PHVS Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PHVS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +11.69%📐 HORIZONTAL RANGE
2026-11-03O $33.58H $33.58L $33.53C $33.53VOL 1.48M
RES: $48.21SUP: $26.81SMA50: $33.54SMA200: $31.08
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PHVS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on PHVS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PHVS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PHVS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PHVS)
Health Care Rank #167 of 1015
⚔️ BHVN vs PHVS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (PHVS vs. BHVN, PBH, RCUS, HCM)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Pharvaris N.V. (PHVS) ranks #167 by composite RQD confidence (59/100, grade C-) and #227 by equity capitalization ($2.34B). Within this direct 5-issuer industry benchmark cohort, HCM leads on earnings valuation at 5.2x trailing P/E, while PBH leads on capital efficiency and profitability with 13.8% ROIC and 54.7% gross margin. PBH currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with PHVS at 59/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PHVS
ACTIVE
Pharvaris N.V. | C- | 59/100 | — | — | — | 0.00% | $2.34B | Benchmark Subject |
| BHVN Biohaven Ltd. | D | 44/100 | — | — | -35.0% | -1.69% | $2.33B | /bhvn-vs-phvs → |
| PBH Prestige Consumer Healthcare Inc. | C | 62/100 | 12.1x | 54.7% | 13.8% | +1.37% | $2.32B | /pbh-vs-phvs → |
| RCUS Arcus Biosciences Inc. | E | 19/100 | — | — | -35.0% | -1.87% | $2.32B | /rcus-vs-phvs → |
| HCM HUTCHMED (China) Limited | E | 34/100 | 5.2x | — | -2.5% | +0.91% | $2.29B | /hcm-vs-phvs → |
2. PHVS Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTPharvaris N.V. (PHVS) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $2.34B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. PHVS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PHVS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Pharvaris N.V. (NASDAQ: PHVS) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $33.53 (0.00% 1D, market cap $2.34B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, PHVS ranks #167 in composite RQD confidence.
How does PHVS compare to BHVN and PBH in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PHVS carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, BHVN (Biohaven Ltd.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $2.33B) and PBH (Prestige Consumer Healthcare Inc.) posts a C grade (62/100 RQD, P/E 12.1x, ROIC 13.8%, cap $2.32B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while PBH leads on capital efficiency (13.8% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PHVS?
For Pharvaris N.V. (PHVS), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #167 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PHVS trading relative to its 50-day, 200-day, and 52-week technical levels?
PHVS last traded at $33.53 (0.00% on volume of 633,473 shares), positioning the stock -0.03% below its 50-day simple moving average ($33.54) and +7.88% above its 200-day simple moving average ($31.08). Across its 52-week range of $21.02 to $43.25, PHVS sits at the 56.3% percentile with a 14-day RSI of 59.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±8.5% ($30.68 to $36.38).
ROARABLE RATING BRIEF • RQD 59/100 (C-)
✓ SEC XBRL & RQD VERIFIED
PHVS — Pharvaris N.V.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03
1. Roarable Rating Brief: What This Means to a Prospective Investor
Pharvaris N.V. (PHVS) earns a live Roarable RQD composite score of 59/100, corresponding to a C- letter grade (Roarable Hold) at a spot price of $33.53 (0.00% 1D, market capitalization $2.34B).
- Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (12/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (13/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Pharvaris N.V. (PHVS) is a NASDAQ-listed issuer classified under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry..3B. — The specific products, customer base, and revenue model are not described in the source data.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (C- • RQD 59/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 12/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 12/20, sustained execution supports upside toward the upper end of the $21.02 – $43.25 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), PHVS carries a macro regime beta of 1.00 and gross margin of —.
- Key Question #1: Can PHVS sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $43.25 52-week high?
- Key Question #3: How sensitive is PHVS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
PHVS Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Pharvaris N.V. (PHVS) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance Australia • 1d ago
Pharvaris N.V. (PHVS) stock price, news, quote and history Yahoo Finance Australia report covering Pharvaris N.V. (PHVS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 1d ago
Pharvaris N.V. (PHVS) Presents at 2026 HAEi Regional Conference Americas - Slideshow Seeking Alpha report covering Pharvaris N.V. (PHVS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 1d ago
Pharvaris stock reiterated Buy at H.C. Wainwright on HAE therapy potential Investing.com report covering Pharvaris N.V. (PHVS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session Benzinga report covering Pharvaris N.V. (PHVS) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Benzinga • 1d ago
Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade Benzinga report covering Pharvaris N.V. (PHVS) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH https://www.siam.in/ • 1d ago
Pharvaris (PHVS) Slips 1.72% to $30.36, Holding the Midpoint of Its Recent Range - Bear Pennant https://www.siam.in/ report covering Pharvaris N.V. (PHVS) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Benzinga • 1d ago
This Allegion Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday Benzinga report covering Pharvaris N.V. (PHVS) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Benzinga • 4d ago
This Monolithic Power Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday Analysts upgraded Incyte, Intel, Rivian and Monolithic Power, raising ratings and targets; MPWR’s target increased to $1,700.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
PHVS Bull vs. Bear Conversation Board — What's Your Call at $33.53?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PHVS 🐻 33% BEARISH CONVICTION
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH
🎯 Target: $41.24 (+23.0%)
📌 Pinned Debate Per the Roarable RQD rating, a 13/20 forensic balance sheet with Altman Z of 2.5 and Piotroski F of 6/9 indicates reasonable financial
The street is overcomplicating Pharvaris N.V. (PHVS). Per the Roarable RQD rating, a 13/20 forensic balance sheet with Altman Z of 2.5 and Piotroski F of 6/9 indicates reasonable financial health, and H.C. Wainwright reiterated a Buy tied to HAE therapy potential.. With an RQD score of 59/100 (C-) and Forensic Balance Sheet at 13/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $36.21.
CapAlloc_Nerd 🐂 BULL
@SkepticalCFA Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH
🎯 Target: $26.15 (-22.0%)
Spot @ $33.53 Per the Roarable RQD rating, ROIC and FCF yield are both 0% and insider conviction scores only 9/20, leaving no demonstrated cash retur
I respect the product at Pharvaris N.V., but the stock at $33.53 is a different story. Per the Roarable RQD rating, ROIC and FCF yield are both 0% and insider conviction scores only 9/20, leaving no demonstrated cash returns or strong insider support.. FCF yield is 0.0% and RQD sits at 59/100 (C-) — why pay up here when you can wait for next quarter's numbers?